EDGC

245620KOSDAQSector: Pharma & Biotech

₩741 0.00%Market cap ₩167.1BAs of Jul 21, 2026 close · updated once daily

Grade D31.8 ptsTop 83% of 2,523 stocks

Financial strength

10.7

Growth momentum

42.3

Price attractiveness

48.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

10.7

How much debt does it carry relative to equity?

Debt-to-equity ratio

Negative equity (not computable)

✗ Below median · Top 99.4% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

31.5%

✗ Below median · Top 98.2% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-20.2%

✗ Below median · Top 60.3% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

Negative equity (not computable)

✗ Below median · Top 99.4% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

42.3

How much did revenue grow in a year?

Revenue growth (YoY)

-74.5%

✗ Below median · Top 97.9% in sector

Sector median 6.4%

Has it grown steadily over three years?

Revenue 3-year CAGR

-56.3%

✗ Below median · Top 98.1% in sector

Sector median 4.9%

Did core profits grow in a year?

Operating income change (YoY)

87.4%

✓ Above median · Top 14.5% in sector

Sector median 3.6%

Are core profits higher than three years ago?

Operating income change (3Y)

83.2%

✓ Above median · Top 20.2% in sector

Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

48.4

Is the price expensive relative to earnings?

P/E (price-to-earnings)

5.9x

✓ Above median · Top 4.3% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

Negative equity (not computable)

✗ Below median · Top 99% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15